Resistance-free SARS-CoV-2 neutralizing drug development with high-affinity modified ACE2 protein.
- Funded by Japan Agency for Medical Research and Development (AMED)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Funder
Japan Agency for Medical Research and Development (AMED)Principal Investigator
Assistant Professor Atsushi HOSHINOResearch Location
JapanLead Research Institution
Department of Cardiovascular medicine, Kyoto Prefectural University of MedicineResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable